ADDYI (flibanserin) by Sprout Pharmaceuticals is p-glycoprotein inhibitors [moa]. First approved in 2015.
Drug data last refreshed 17h ago · AI intelligence enriched 1mo ago
ADDYI (flibanserin) is an oral small molecule tablet approved in 2015 for women's sexual health, working through P-glycoprotein inhibition to modulate neurotransmitter activity. It addresses a niche indication with limited treatment options and a highly specific patient demographic. The drug operates on a unique mechanism distinct from hormonal or vascular approaches in its therapeutic area.
With 1.6 years to LOE, the brand team is in transition planning mode; expect downsizing or redeployment of commercial staff rather than growth.
P-Glycoprotein Inhibitors
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Bioequivalence Study of Flibanserin From AphroFemine 100 mg F.C.T (Bio Med for Pharmaceuticals Industries (BIOMED), Egypt) Versus Addyi 100 mg Tablets (Sprout Pharmaceuticals, Inc., USA)
Pharmacokinetics of Flibanserin in Postmenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)
A 28-week Safety Study of Flibanserin in Pre- and Postmenopausal Women With Hypoactive Sexual Desire Disorder
Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women in North America
12 Week Safety Trial of Flibanserin in Depressed Women Taking an SSRI or SNRI With Decreased Sexual Desire and Distress
Worked on ADDYI at Sprout Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moPatent cliff in ~2 years — expect lifecycle management and generic defense hiring
Working on ADDYI offers insight into niche market commercialization, women's health advocacy, and LOE transition management—valuable skills but in a sunset product. Professionals should prioritize demonstrating pipeline readiness and strategic planning for post-LOE careers.